Bone growth stimulators can now reach patients with less regulatory delay

US health regulators just moved non-invasive bone growth stimulators from the highest risk category to a lower one. This means manufacturers can get these devices to market faster, without needing to prove their safety and effectiveness from scratch.

For years, new medical devices faced a long, expensive approval process, even if they were similar to existing products. This change means that devices like bone growth stimulators, which are already well-understood, can now be approved based on established safety controls. It should lower development costs and speed up patient access for these specific devices.